Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter - ScienceDirect
Place des marqueurs sériques en cancérologie digestive – FMC-HGE
Lewis antigen‑negative pancreatic cancer: An aggressive subgroup
Les marqueurs tumoraux - ppt télécharger
Comparison of the Normal CA 19-9 Level Group and Elevated CA 19-9 Level... | Download Scientific Diagram
CA19-9 Antibody (121SLE) - Bio SB
CA 19-9: handle with care
Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
CA 19-9: handle with care
Serum Cancer Antigen 19-9 (CA 19-9) and total bilirubin concentrations... | Download Scientific Diagram
CA-19-9 - Diagnostic Kit
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer - ScienceDirect
CA 19-9 Antigen - an overview | ScienceDirect Topics
Highly Sensitive Plasmonic Detection of the Pancreatic Cancer Biomarker CA 19-9 | Scientific Reports
Tumor Marker CA 19-9 for Assessing Pancreatic Cancer Response - Cancer Therapy Advisor
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports
How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? - ScienceDirect
Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome | British Journal of Cancer
Cancers | Free Full-Text | Complementary Use of Carbohydrate Antigens Lewis a, Lewis b, and Sialyl-Lewis a (CA19.9 Epitope) in Gastrointestinal Cancers: Biological Rationale towards a Personalized Clinical Application
Marqueurs tumoraux : quelle utilité en pratique clinique ?
Place des marqueurs sériques en cancérologie digestive – FMC-HGE
CA 19 .9 | RT Diagnostics
The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer Cells | Scientific Reports
Frontiers | Value of Carbohydrate Antigen 19-9 in Predicting Response and Therapy Control in Patients with Metastatic Pancreatic Cancer Undergoing First-Line Therapy
Marqueurs tumoraux : quelle utilité en pratique clinique ?